000			01752 a2200505 4500
005			20250516063900.0
264		0	_c20121018
008			201210s 0 0 eng d
022			_a1536-4844
024	7		_a10.1002/ibd.21929 _2doi
040			_aNLM _beng _cNLM
100	1		_aJohnson, Laura A
245	0	0	_aSpironolactone and colitis: increased mortality in rodents and in humans. _h[electronic resource]
260			_bInflammatory bowel diseases _cJul 2012
300			_a1315-24 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural
650	0	4	_aAnimals
650	0	4	_aClostridioides difficile _xpathogenicity
650	0	4	_aClostridium Infections _xdrug therapy
650	0	4	_aColitis _xcomplications
650	0	4	_aCrohn Disease _xdrug therapy
650	0	4	_aFemale
650	0	4	_aFibrosis _xdrug therapy
650	0	4	_aHospitalization
650	0	4	_aHumans
650	0	4	_aInflammation _xdrug therapy
650	0	4	_aIntestinal Diseases _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMineralocorticoid Receptor Antagonists _xtherapeutic use
650	0	4	_aMyofibroblasts _xcytology
650	0	4	_aRats
650	0	4	_aRetrospective Studies
650	0	4	_aSpironolactone _xtherapeutic use
650	0	4	_aSurvival Rate
650	0	4	_aTransforming Growth Factor beta _xpharmacology
650	0	4	_aTrinitrobenzenesulfonic Acid _xtoxicity
700	1		_aGovani, Shail M
700	1		_aJoyce, Joel C
700	1		_aWaljee, Akbar K
700	1		_aGillespie, Brenda W
700	1		_aHiggins, Peter D R
773	0		_tInflammatory bowel diseases _gvol. 18 _gno. 7 _gp. 1315-24
856	4	0	_uhttps://doi.org/10.1002/ibd.21929 _zAvailable from publisher's website
999			_c21309858 _d21309858